MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Design Therapeutics Inc

Fermé

5.68 -7.64

Résumé

Variation du prix de l'action

24h

Actuel

Min

5.66

Max

5.74

Chiffres clés

By Trading Economics

Revenu

-1.4M

-19M

Marge bénéficiaire

-2,321.599

Employés

57

EBITDA

-1.3M

-22M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

-12.89% downside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

159M

384M

Ouverture précédente

13.32

Clôture précédente

5.68

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Design Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 oct. 2025, 18:13 UTC

Principaux Mouvements du Marché

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17 oct. 2025, 17:05 UTC

Principaux Mouvements du Marché

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

18 oct. 2025, 13:30 UTC

Acquisitions, Fusions, Rachats

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 oct. 2025, 13:30 UTC

Acquisitions, Fusions, Rachats

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 oct. 2025, 13:30 UTC

Acquisitions, Fusions, Rachats

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 oct. 2025, 13:30 UTC

Acquisitions, Fusions, Rachats

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 oct. 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

17 oct. 2025, 23:25 UTC

Acquisitions, Fusions, Rachats

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 oct. 2025, 22:15 UTC

Market Talk

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 oct. 2025, 21:15 UTC

Market Talk

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17 oct. 2025, 21:07 UTC

Market Talk

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17 oct. 2025, 21:07 UTC

Market Talk

Global Equities Roundup: Market Talk

17 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 oct. 2025, 20:34 UTC

Market Talk

Deere Is Reaching the End of Its Downcycle -- Market Talk

17 oct. 2025, 20:27 UTC

Market Talk

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17 oct. 2025, 19:46 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17 oct. 2025, 19:45 UTC

Market Talk

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17 oct. 2025, 18:45 UTC

Market Talk

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17 oct. 2025, 17:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 oct. 2025, 17:51 UTC

Market Talk

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17 oct. 2025, 17:44 UTC

Market Talk

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17 oct. 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17 oct. 2025, 16:20 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

17 oct. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 oct. 2025, 16:14 UTC

Market Talk

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17 oct. 2025, 16:04 UTC

Market Talk

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17 oct. 2025, 15:58 UTC

Market Talk

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17 oct. 2025, 15:56 UTC

Résultats

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17 oct. 2025, 15:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17 oct. 2025, 15:43 UTC

Market Talk

Amazon's Earnings Are About Sentiment of Consumers, Not Investors -- Market Talk

Comparaison

Variation de prix

Design Therapeutics Inc prévision

Objectif de Prix

By TipRanks

-12.89% baisse

Prévisions sur 12 Mois

Moyen 5 USD  -12.89%

Haut 5 USD

Bas 5 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

2 ratings

0

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

3.26 / 3.63Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
help-icon Live chat